Novartis in-licenses COVID-19 treatment ensovibep from Molecular Partners

Reuters2022-01-10

ZURICH, Jan 10 (Reuters) - Novartis(NOVN.S)said it will license in a new drug it has been developing with Molecular Partners to treat COVID-19, the Swiss company said on Monday, after getting positive...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

shawnhuat
2022-01-10
shawnhuat
K
VickJW
2022-01-10
VickJW
Like and comment
Jellywonka
2022-01-10
Jellywonka
Tell me your opinion about this news...
Jellywonka
2022-01-10
Jellywonka
ok

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1195083513?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-01-10 17:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195083513","market":"us","top_or_hot":-1,"title":"Novartis in-licenses COVID-19 treatment ensovibep from Molecular Partners","media":"Reuters","content":"<div>\n<p>ZURICH, Jan 10 (Reuters) - Novartis(NOVN.S)said it will license in a new drug it has been developing with Molecular Partners to treat COVID-19, the Swiss company said on Monday, after getting positive...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-in-licenses-covid-19-treatment-ensovibep-molecular-partners-2022-01-10/\">Source Link</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis in-licenses COVID-19 treatment ensovibep from Molecular Partners</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis in-licenses COVID-19 treatment ensovibep from Molecular Partners\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-10 17:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-in-licenses-covid-19-treatment-ensovibep-molecular-partners-2022-01-10/><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ZURICH, Jan 10 (Reuters) - Novartis(NOVN.S)said it will license in a new drug it has been developing with Molecular Partners to treat COVID-19, the Swiss company said on Monday, after getting positive...</p>\n\n<a href=\"https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-in-licenses-covid-19-treatment-ensovibep-molecular-partners-2022-01-10/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MOLN","symbol_name":"Molecular Partners AG","start_time":0,"source_url":"https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-in-licenses-covid-19-treatment-ensovibep-molecular-partners-2022-01-10/","article_id":"1195083513","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195083513","pubTimestamp":1641806835,"sourceInfo":null,"weMediaInfo":null,"summary":"ZURICH, Jan 10 (Reuters) - Novartis(NOVN.S)said it will license in a new drug it has been developing","collect":0,"end_time":0,"defaultTopTitle":"reuters.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MOLN":"Molecular Partners AG","NVS":"诺华"},"translate_title":"诺华从分子合作伙伴那里获得新冠肺炎治疗ENSIOVBEP的许可","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MOLN":0.9,"NVS":0.9},"content_text":"ZURICH, Jan 10 (Reuters) - Novartis(NOVN.S)said it will license in a new drug it has been developing with Molecular Partners to treat COVID-19, the Swiss company said on Monday, after getting positive trial data.Novartis will pay 150 million Swiss francs ($162.92 million) to in-license ensovibep from Molecular Partners to speed up its manufacturing ramp up and get approvals for the drug more quickly.The decision comes after the two companies said they had received positive topline data from a phase 2 study for ensovibep (mp0420), an antiviral therapeutic for COVID-19 that will from now on be developed and manufactured by Novartis.Molecular Partners had already received an upfront payment of 60 million francs, including equity.The DARPin (Designed Ankyrin Repeat Protein) antiviral therapeutic candidate met the primary endpoint of viral load reduction over eight days in a study in acute COVID-19 ambulatory patients comparing single intravenous doses of ensovibep versus placebo, the two companies said in a statement.The two secondary endpoints also showed a clinically meaningful benefit compared with a placebo, the partners said.Novartis will first seek the approval from the U.S. Food and Drug Administration (FDA), where it is applying for an Emergency Use Authorization (EUA).DARPins offer a differentiated approach to treating COVID-19 through a single molecule that can engage up to three parts of the SARS-CoV-2 virus simultaneously to neutralize the virus through multiple mechanisms, Molecular Partners said on its website.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9006404347,"gmtCreate":1641808689564,"gmtModify":1676533649603,"author":{"id":"3575420754880245","authorId":"3575420754880245","name":"shawnhuat","avatar":"https://static.tigerbbs.com/ce96f5461b1fd7c34fc7f8592a7eb525","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3575420754880245","authorIdStr":"3575420754880245"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006404347","repostId":1195083513,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9006402657,"gmtCreate":1641807834287,"gmtModify":1676533649544,"author":{"id":"3578439260866475","authorId":"3578439260866475","name":"VickJW","avatar":"https://static.tigerbbs.com/dc8189137ac06a254539a020b5b368b2","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3578439260866475","authorIdStr":"3578439260866475"},"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006402657","repostId":1195083513,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9006402942,"gmtCreate":1641807709567,"gmtModify":1676533649535,"author":{"id":"3570614147611531","authorId":"3570614147611531","name":"Jellywonka","avatar":"https://static.tigerbbs.com/b9774fac6cdbae1bac77d81d9922fb02","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3570614147611531","authorIdStr":"3570614147611531"},"htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006402942","repostId":1195083513,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9006402001,"gmtCreate":1641807702876,"gmtModify":1676533649553,"author":{"id":"3570614147611531","authorId":"3570614147611531","name":"Jellywonka","avatar":"https://static.tigerbbs.com/b9774fac6cdbae1bac77d81d9922fb02","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3570614147611531","authorIdStr":"3570614147611531"},"htmlText":"ok","listText":"ok","text":"ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006402001","repostId":1195083513,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":48,"commentSize":4,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1195083513"}